Form D · Pharmaceuticals
Lyell Immunopharma, Inc.
South San Francisco, CA · CIK 0001806952
Offering snapshot reported Mar 20, 2020 · SEC filing
- Reported sold
- $493M Offering amount: $493M
- Investors reported
- 10 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Mar 5, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 20, 2020 | Initial | $492,999,957 | No comparison | 10 | SEC filing |
Offering details
- Securities
- Equity, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-363351
Sale and issuance of Series C Preferred Stock ("Series C") and the underlying shares of Common Stock issuable upon conversion of Series C.
Source: Form D, filed Mar 20, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Hans Bishop | Director |
| Catherine Friedman | Director |
| Richard Goold | Executive |
| Stephen Hill | Executive |
| Elizabeth Homans | Executive |
| Richard Klausner | Director, Executive, Promoter |
| Robert Nelson | Director |
| Nicholas Restifo | Executive |
| Stan Riddell | Executive |
| Margo Roberts | Executive |
| Heather Turner | Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
400 East Jamie Court Suite 301
South San Francisco, CA, 94080
South San Francisco, CA, 94080